Yourgene Health PLC Distribution Partnership
May 19 2021 - 2:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
19 May 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Distribution Partnership for the Middle East and Africa
Yourgene and Alliance Global launch partnership across multiple
territories
Manchester, UK - 19 May 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that it is
launching a Distribution Partnership with Dubai-headquartered
Alliance Global FZ LLC ('AGBL' or 'Alliance Global') across a broad
range of territories in the Middle East and Africa to expand the
Company's geographical footprint and its customer base.
Alliance Global is the largest biomedical gateway in the Middle
East, Africa, and Asia and is both a well-respected and a long-term
partner for many international and U.S. diagnostics groups looking
to pursue a strategy of expansion in these regions. The group is
dedicated to bringing innovative technologies and products to
researchers, clinicians, and diagnostic users in the regions'
emerging healthcare market. AGBL is a well-positioned platform
agnostic partner for Yourgene, working with key providers of both
PCR and sequencing technologies. AGBL will be focusing on
Yourgene's product portfolio of non-invasive prenatal testing
('NIPT'), the reproductive health range including Cystic Fibrosis
and QST*R rapid aneuploidy analysis, DPYD genotyping and the new
size selection and enrichment technologies, Yourgene QS250 and
LightBench(TM).
In response to the restriction on travel to key regions as a
result of the COVID-19 pandemic, Yourgene has reviewed it's
strategy for bringing products to market in new territories.
Following a review of the Company's channels across its
international markets, the commitment and focus with a local
network in the Middle East and Africa provided by AGBL, is expected
to generate future growth opportunities for the Company. AGBL has
strong technical expertise to distribute and support Yourgene's
growing product range and customer base across these regions,
offering an expansive geographic reach and more commercial drivers
on the ground to meet the needs of this exciting, emerging
international market.
Commenting, Lyn Rees, CEO of Yourgene, said: "This partnership
with AGBL is a really exciting progression for Yourgene and our
product portfolio as we continue to expand into further
territories. AGBL will provide a strong and well positioned channel
to allow us to deliver and drive growth for our current and future
products. This is a key international market for Yourgene and we
look forward to working with AGBL and utilising their expertise to
secure further market penetration and geographic expansion."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFEFUAEFSEEI
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024